De novo everolimus for recipients of kidney transplants from HLA identical donors

Cristelli, Marina Pontello; Ferreira, Alexandra; Hannun, Pedro; Felipe, Cláudia Rosso; Aguiar, Wilson; Franco, Marcello; Tedesco‐Silva, Hélio; Medina‐Pestana, José Osmar

doi:10.5935/0101-2800.20160032

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…studied a cohort of 39 HLA‐identical LKT who were initially put on corticosteroids, tacrolimus and everolimus, with early discontinuation of tacrolimus (at 1‐month post‐KT) and maintenance of corticosteroids with everolimus. They observed an acute rejection incidence of 15.4% at 12 months post‐KT, and all these episodes occurred after the discontinuation of the CNI 30 . In this study, the authors concluded that the new everolimus‐based immunosuppressive regimen, with planned early withdrawal of CNI was not effective for HLA‐identical KTRs, particularly due to a high incidence of acute rejection.…”

Section: Discussionmentioning

confidence: 73%

“…They observed an acute rejection incidence of 15.4% at 12 months post-KT, and all these episodes occurred after the discontinuation of the CNI. 30 In this study, the authors concluded that the new everolimus-based immunosuppressive regimen, with planned early withdrawal of CNI was not effective for HLA-identical KTRs, particularly due to a high incidence of acute rejection. In the context of HLA-identical LKT, acute rejection is related to the production of HLA antibodies and/or non-HLA antibodies.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

HLA‐identical living related kidney transplantation: Outcomes of a national multicenter study

Bentata¹,

Elkabbaj²,

Bahadi³

et al. 2022

Int J of Urology

View full text Add to dashboard Cite

The kidney prognosis of HLA-identical seems theoretically very interesting with the lowest risk of acute rejection after that of identical twins. Objectives were to determine the prevalence of acute rejection and various complications in a cohort of HLA-identical living-related kidney transplant. Methods: A retrospective, multicenter study was conducted in seven university centers in Morocco, which included all recipients of an HLA-identical living-related kidney transplant performed between 1990 and 2019. Results: Data on 68 HLA-identical living-related kidney transplants were collected. The donors were siblings in 89.7%, the parents in 7.3%, and identical twins in 3% of cases. 53.6% of all recipients were under 35 years old, and 59.4% of them were male. 39.7% of all donors were under 35 years old, and 47% of them were male. 48.5% of HLA-identical living-related kidney transplants were performed before the year 2000. 18 kidney transplant biopsies were performed on 16 kidney transplant recipients. Seven episodes of acute rejection occurred in six patients, 8.8% of the whole cohort (n = 68). Two cases of acute rejection among the seven were related to poor adherence, cessation of immunosuppressive therapy, and loss of medical follow-up by these patients. These two patients were 20 years old at the time of kidney transplantation. The global kidney transplant survival was 66.7% versus 91.9% (P = 0.04) in the two patient groups having developed acute rejection and not having developed acute rejection, respectively. Conclusions: Acute rejection is a real threat to HLA-identical kidney transplant recipients. Therefore, it seems very important to codify the immunosuppressive regimen and to adopt a minimal and effective treatment.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 82%

HLA‐identical living related kidney transplantation: Outcomes of a national multicenter study

Bentata¹,

Elkabbaj²,

Bahadi³

et al. 2022

Int J of Urology

View full text Add to dashboard Cite

show abstract

Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL Study

et al. 2020

View full text Add to dashboard Cite

Background. We aimed to describe the immunosuppressive regimens and graft rejection rates in living-related HLA-identical (LR HLAid) renal transplantation. Methods. We performed a retrospective multicenter analysis of the French national database for LR HLAid renal transplantations performed between 2002 and 2012. Univariate and multivariate analysis were performed to determine risk factors for graft rejection in LR HLAid recipients. Results. A total of 27 218 renal transplantations were performed, of whom 163 had a LR HLAid donor. About immunosuppressive treatment, <60% of the cohort had induction therapy with polyclonal or monoclonal antibodies, 28% did not receive calcineurin inhibitors, and 36% did not receive steroids in maintenance. Biopsy-proven acute rejection was diagnosed in 21 patients (12.9%). Rejection occurred on an average of 24 months after transplantation, in 28.5% of the cases after minimization of immunosuppression. Factors associated with rejection were age of recipient (OR, 0.91 [0.84–0.96]; P = 0.003), the body mass index of donors (odds ratio [OR], 1.22 [1.04–1.46]; P = 0.01), and minimization of immunosuppression (OR, 26.2 [5.48–166.6]; P < 0.001). Overall and graft survival rates were not statistically different according to rejection at 1, 5, and 10 years posttransplantation. Conclusions. Minimization of immunosuppression should be done with caution in LR HLAid renal transplantations.

show abstract

De novo everolimus for recipients of kidney transplants from HLA identical donors

Abstract: The proposed scheme was not effective for this population, particularly due to a high incidence of acute rejection. Safety profile showed that prolonged exposure to a high concentration of blood EVR increases the incidence of adverse events related to this drug.

Cited by 2 publications

References 0 publications

HLA‐identical living related kidney transplantation: Outcomes of a national multicenter study

HLA‐identical living related kidney transplantation: Outcomes of a national multicenter study

Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL Study

Contact Info

Product

Resources

About